Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Venetoclax Combined With Azacitidine Induction and Bridging to Allo-HSCT for Hypoplastic or Secondary AML
NCT07635485Not yet recruiting
- Sponsor
- First Affiliated Hospital of Soochow University
- Start
- Jun 2026
- Primary completion
- May 2029
- Countries
- 1
01
Overview
Open-label, single-arm trial of venetoclax and azacitidine in Hypoplastic acute myeloid leukemia (h-AML) and acute myeloid leukemia (AML), sponsored by First Affiliated Hospital of Soochow University. Primary endpoint: Overall Survival at 2 years. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
venetoclaxazacitidine
03
Conditions
Hypoplastic acute myeloid leukemia (h-AML)acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT07635485.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07635485.